Association of Plasma B-Type Natriuretic Peptide Concentrations With Longitudinal Blood Pressure Tracking in African Americans: Findings From the Jackson Heart Study

Water and sodium retention precedes the development of high blood pressure (BP) and explains a compensatory rise in B-type natriuretic peptide (BNP) concentrations. It is unclear whether BNP concentrations antedate the BP progression. We hypothesized that higher BNP concentrations in our African American cohort will be associated with longitudinal increases in BP, progression of BP stage, and incident hypertension. Our study sample consisted of 888 normotensive (based on BP at examination 1 [2000–2004]) participants of the Jackson Heart Study (mean age, 47±12 years; 61% women). We examined the relation of BNP concentrations at the baseline examination to change in systolic and diastolic BPs, BP progression (an increase by 1 BP stage as defined by THE sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) and incident hypertension by examination 2 (2005–2008) adjusting for baseline BP stages, systolic and diastolic BPS, traditional risk factors, and echocardiographic left ventricular mass. Over a median follow-up period of 5.0±0.8 years, 36.9% progressed to a higher BP stage and 19.3% developed hypertension. In multivariable regression models, higher log-BNP concentrations at examination 1 were significantly and positively associated with changes in systolic and diastolic BPs (P<0.05 for both). Baseline log-BNP was significantly associated with BP progression (P=0.046). Every SD increase in baseline log BNP was associated with a 12% increased risk of BP progression. Log-BNP was not significantly associated with incident hypertension (P=0.12). In our community-based sample of African Americans, higher BNP concentrations predicted a longitudinal increase in systolic and diastolic BPs and progression of BP stage.

[1]  V. Howard,et al.  Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. , 2011, American journal of hypertension.

[2]  W. Pan,et al.  Differential endothelial cell gene expression by African Americans versus Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer , 2011, BMC medicine.

[3]  W. Roberts,et al.  The editor's roundtable: Hypertension in African Americans and other non-Caucasian ethnic groups. , 2010, The American journal of cardiology.

[4]  Tae Ik Kim,et al.  N-Terminal Pro-B-Type Natriuretic Peptide in Overweight and Obese Patients With and Without Diabetes: An Analysis Based on Body Mass Index and Left Ventricular Geometry , 2009, Korean circulation journal.

[5]  K. Fiscella,et al.  Racial Disparity in Hypertension Control: Tallying the Death Toll , 2008, The Annals of Family Medicine.

[6]  G. Mitchell Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. , 2008, Journal of applied physiology.

[7]  W. Nichols,et al.  Effects of Arterial Stiffness, Pulse Wave Velocity, and Wave Reflections on the Central Aortic Pressure Waveform , 2008, Journal of clinical hypertension.

[8]  A. Richards,et al.  Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use , 2007, Hypertension.

[9]  J. Burnett,et al.  Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. , 2006, American journal of physiology. Heart and circulatory physiology.

[10]  C. Moy,et al.  Racial and Geographic Differences in Awareness, Treatment, and Control of Hypertension: The REasons for Geographic And Racial Differences in Stroke Study , 2006, Stroke.

[11]  J. Hradec,et al.  Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration , 2006, Blood pressure.

[12]  Nuala A Sheehan,et al.  Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure , 2005, Statistics in medicine.

[13]  P. W. Leeuw,et al.  Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology , 2005, Fundamental & clinical pharmacology.

[14]  D. Lloyd‐Jones,et al.  Hypertension in adults across the age spectrum: current outcomes and control in the community. , 2005, JAMA.

[15]  J. Kato,et al.  Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. , 2004, American journal of hypertension.

[16]  G. Wambach,et al.  Plasma levels of atrial natriuretic peptide are raised in essential hypertension during low and high sodium intake , 1987, Klinische Wochenschrift.

[17]  M. Andrew,et al.  Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description. , 2005, Ethnicity & disease.

[18]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[19]  D. Levy,et al.  Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study , 2003, Hypertension.

[20]  H. Taylor Establishing a foundation for cardiovascular disease research in an African-American community--the Jackson Heart Study. , 2003, Ethnicity & disease.

[21]  Pedro Lozano Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[22]  R. Latini,et al.  Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. , 2002, Journal of cardiac failure.

[23]  Daniel Levy,et al.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.

[24]  Y. Yazaki,et al.  Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. , 2001, Cardiovascular research.

[25]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci. 28:89-94, 1981. , 2001, Journal of the American Society of Nephrology : JASN.

[26]  R. Sarzani,et al.  The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. , 1998, Journal of nephrology.

[27]  G. Sagnella Measurement and significance of circulating natriuretic peptides in cardiovascular disease. , 1998, Clinical science.

[28]  M. Bold Atrial Natriuretic Factor and Brain Natriuretic Peptide Gene Expression in the Spontaneous Hypertensive Rat During Postnatal Development , 1998 .

[29]  M. L. Kuroski de Bold Atrial natriuretic factor and brain natriuretic peptide gene expression in the spontaneous hypertensive rat during postnatal development. , 1998, American journal of hypertension.

[30]  T. Ishimitsu,et al.  Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. , 1996, Hypertension.

[31]  B. Bruneau,et al.  Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. , 1996, Circulation.

[32]  S. Turner,et al.  Atrial natriuretic peptide and blood pressure in a population-based sample. , 1995, Mayo Clinic proceedings.

[33]  D. Levy,et al.  Hemodynamic predictors of incident hypertension. The Framingham Heart Study. , 1994, Hypertension.

[34]  N. Markandu,et al.  Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. , 1993, Journal of human hypertension.

[35]  S. Daniels,et al.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. , 1992, Journal of the American College of Cardiology.

[36]  T. Horio,et al.  Brain natriuretic peptide as a cardiac hormone in essential hypertension. , 1992, The American journal of medicine.

[37]  K. Murata,et al.  Plasma levels of atrial natriuretic peptide in patients with borderline and essential hypertension. , 1988, The Tohoku journal of experimental medicine.

[38]  A. Richards,et al.  Correlates of plasma atrial natriuretic factor in health and hypertension. , 1987, Hypertension.

[39]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[40]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.